Carney complex (PRKAR1A) gene panel

Carney Complex (PRKAR1A) Gene Panel

The Carney Complex (PRKAR1A) Gene Panel is a specialized genetic test used to identify mutations in the PRKAR1A gene associated with Carney Complex (CNC), a rare hereditary disorder characterized by multiple endocrine tumors, cardiac myxomas, skin pigmentation abnormalities, and other neoplasms. This test helps in early diagnosis, risk assessment, family screening, and long-term clinical management.

What is Carney Complex?

Carney Complex is an autosomal dominant genetic syndrome caused primarily by pathogenic variants in the PRKAR1A gene. The condition may involve:

• Cardiac myxomas
• Skin lentigines and blue nevi
• Endocrine tumors
• Pituitary adenomas
• Adrenal gland abnormalities
• Thyroid and testicular tumors
• Schwannomas

PRKAR1A mutations are identified in over 70% of affected individuals.

Gene Included

• PRKAR1A

Why is this Test Done?

This panel is recommended for individuals with:

• Recurrent cardiac myxomas
• Multiple endocrine tumors
• Characteristic skin pigmentation
• Family history of Carney Complex
• Early-onset adrenal or pituitary disease
• Suspected hereditary tumor syndromes

Test Methodology

• Next Generation Sequencing (NGS)
• Deletion/Duplication Analysis (if applicable)

Sample Required

• Peripheral blood sample

Benefits of Testing

• Early diagnosis of hereditary cancer/tumor syndromes
• Identification of at-risk family members
• Personalized surveillance and treatment planning
• Better clinical management and preventive care

Inheritance Pattern

Carney Complex is inherited in an autosomal dominant manner, meaning a single altered copy of the gene can cause the condition.

Clinical Significance of PRKAR1A

The PRKAR1A gene regulates Protein Kinase A (PKA) signaling involved in cell growth and proliferation. Mutations can lead to uncontrolled cellular growth and tumor formation.

Who Should Consider This Test?

• Individuals with unexplained myxomas
• Patients with endocrine overactivity
• Families with known PRKAR1A mutations
• Individuals with multiple benign tumors and pigmentation changes

Turnaround Time

• Typically 2–4 weeks depending on laboratory workflow

Interpretation

• Positive: Pathogenic mutation detected
• Negative: No clinically significant mutation identified
• VUS: Variant of uncertain significance detected

For accurate interpretation, genetic counseling is recommended alongside clinical correlation.